Thanigaivelan Kanagasabai
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 5 | 2024 | 1068 | 0.920 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2021 | 12 | 0.730 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2021 | 23 | 0.720 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2019 | 41 | 0.620 |
Why?
|
| Imidazoles | 1 | 2019 | 138 | 0.600 |
Why?
|
| Piperazines | 1 | 2019 | 117 | 0.600 |
Why?
|
| Cell Proliferation | 6 | 2024 | 1420 | 0.590 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2018 | 62 | 0.570 |
Why?
|
| Pyridinium Compounds | 1 | 2017 | 27 | 0.550 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 287 | 0.530 |
Why?
|
| Indoles | 1 | 2017 | 178 | 0.490 |
Why?
|
| MicroRNAs | 1 | 2021 | 501 | 0.470 |
Why?
|
| Cell Movement | 2 | 2024 | 640 | 0.460 |
Why?
|
| S-Phase Kinase-Associated Proteins | 2 | 2024 | 23 | 0.440 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 2 | 2024 | 12 | 0.380 |
Why?
|
| Apoptosis | 4 | 2024 | 1541 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2024 | 297 | 0.330 |
Why?
|
| Mice | 10 | 2024 | 6490 | 0.320 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 1679 | 0.310 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 479 | 0.290 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2018 | 32 | 0.280 |
Why?
|
| Cell Line, Tumor | 7 | 2024 | 2598 | 0.270 |
Why?
|
| Neovascularization, Pathologic | 2 | 2018 | 137 | 0.260 |
Why?
|
| Signal Transduction | 3 | 2024 | 2111 | 0.230 |
Why?
|
| Pseudomonas | 1 | 2024 | 8 | 0.230 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2024 | 31 | 0.220 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2024 | 339 | 0.210 |
Why?
|
| Breast Neoplasms, Male | 1 | 2024 | 8 | 0.210 |
Why?
|
| Animals | 10 | 2024 | 16695 | 0.210 |
Why?
|
| Killer Cells, Natural | 1 | 2024 | 99 | 0.210 |
Why?
|
| Receptors, Androgen | 1 | 2024 | 144 | 0.210 |
Why?
|
| Autophagy | 1 | 2024 | 136 | 0.210 |
Why?
|
| Disease Progression | 2 | 2024 | 661 | 0.190 |
Why?
|
| Nuclear Proteins | 2 | 2024 | 330 | 0.190 |
Why?
|
| Environmental Pollutants | 1 | 2024 | 198 | 0.190 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2021 | 12 | 0.180 |
Why?
|
| Repressor Proteins | 2 | 2024 | 267 | 0.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 130 | 0.180 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 13 | 0.180 |
Why?
|
| Poly I-C | 1 | 2021 | 7 | 0.180 |
Why?
|
| Withanolides | 1 | 2021 | 10 | 0.180 |
Why?
|
| Male | 9 | 2024 | 22779 | 0.180 |
Why?
|
| Humans | 12 | 2024 | 42163 | 0.170 |
Why?
|
| Mitochondria | 1 | 2024 | 516 | 0.170 |
Why?
|
| Mice, Nude | 2 | 2021 | 403 | 0.160 |
Why?
|
| CDC2 Protein Kinase | 1 | 2019 | 20 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2019 | 56 | 0.160 |
Why?
|
| Immunotherapy | 1 | 2021 | 137 | 0.160 |
Why?
|
| Biological Products | 1 | 2021 | 91 | 0.150 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 239 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 933 | 0.140 |
Why?
|
| Mucin-1 | 1 | 2018 | 11 | 0.140 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 60 | 0.130 |
Why?
|
| Transcription Factors | 1 | 2021 | 722 | 0.120 |
Why?
|
| Mice, Knockout | 3 | 2024 | 1010 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 979 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2024 | 1804 | 0.080 |
Why?
|
| Female | 4 | 2024 | 24018 | 0.070 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2024 | 4 | 0.060 |
Why?
|
| Biocatalysis | 1 | 2024 | 30 | 0.060 |
Why?
|
| Biodegradation, Environmental | 1 | 2024 | 82 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2024 | 141 | 0.050 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2024 | 71 | 0.050 |
Why?
|
| Androgens | 1 | 2024 | 107 | 0.050 |
Why?
|
| Receptor, Adenosine A2B | 1 | 2023 | 5 | 0.050 |
Why?
|
| Memory Disorders | 1 | 2024 | 77 | 0.050 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2023 | 6 | 0.050 |
Why?
|
| Phosphates | 1 | 2023 | 54 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2024 | 168 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2023 | 49 | 0.050 |
Why?
|
| Adenosine | 1 | 2023 | 62 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2024 | 112 | 0.050 |
Why?
|
| Ubiquitination | 1 | 2023 | 60 | 0.050 |
Why?
|
| Lysosomes | 1 | 2023 | 88 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2024 | 222 | 0.050 |
Why?
|
| Astrocytes | 1 | 2024 | 244 | 0.050 |
Why?
|
| Interferon Inducers | 1 | 2021 | 2 | 0.040 |
Why?
|
| Hippocampus | 1 | 2024 | 591 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 48 | 0.040 |
Why?
|
| Incidence | 1 | 2024 | 1054 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2024 | 548 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 233 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 77 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 506 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 134 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 686 | 0.040 |
Why?
|
| Inflammation | 1 | 2024 | 729 | 0.040 |
Why?
|
| Laminin | 1 | 2018 | 58 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2018 | 49 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2018 | 102 | 0.030 |
Why?
|
| Collagen | 1 | 2018 | 178 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 557 | 0.030 |
Why?
|
| Brain | 1 | 2024 | 1452 | 0.030 |
Why?
|
| Risk Factors | 1 | 2024 | 3942 | 0.030 |
Why?
|